SHetA2 combination therapy for cancer
SHetA2 is a novel, orally bioavailable, small molecule drug with low toxicity being developed for clinical trials based on its induction of apoptosis in cancer cells. Combination of SHetA2 (which binds to mortalin and causes the release and nuclear accumulation of p53) with a p53 reactivator drug inhibited ovarian cancer cell line growth in vitro and tumor establishment in vivo. This technology presents a novel approach to the prevention of tumor establishment and recurrence.
IP status: 6,586,460 (US); 7,612,107 (US); 62/730,345